The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00833131 |
Recruitment Status : Unknown
Verified April 2010 by Polish Colorectal Cancer Study Group.
Recruitment status was: Recruiting
First Posted : January 30, 2009
Last Update Posted : April 15, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rectal Cancer | Radiation: Short course of radiotherapy Radiation: Radiochemotherapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 540 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study |
Study Start Date : | November 2008 |
Estimated Primary Completion Date : | November 2012 |
Estimated Study Completion Date : | November 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
|
Radiation: Short course of radiotherapy
5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
Other Names:
|
Active Comparator: 2
Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
|
Radiation: Radiochemotherapy
28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
Other Name: chemoradiation |
- The rate of patients with R0 resection [ Time Frame: Surrogate endpoint available immediatly after surgery ]
- Overall long-term survival [ Time Frame: 5 years ]
- Progression-free long-term survival [ Time Frame: 5 years ]
- The rate of local failures [ Time Frame: 5 years ]
- The rate of distant metastases [ Time Frame: 5 years ]
- The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 3.0) [ Time Frame: 3 months ]
- The rate of postoperative complications [ Time Frame: 30 days ]
- The rate of late toxicity according to the RTOG/EORTC scale [ Time Frame: 5 years ]
- The rate of complete pathological response [ Time Frame: Surrogate endpoint available immediatly after surgery ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with unresectable primary rectal cancer or with unresectable local recurrence without distant metastases.
- WHO performance status ≤ 2.
- Lower border of tumour ≤ 15 cm from anal verge.
Exclusion Criteria:
- cardiac coronary arterial disease,
- arrhythmias,
- stroke even if they have occurred in the past and are controlled with medication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00833131
Contact: Wojciech Michalski, M. S. | +48226433909 | W.Michalski@coi.waw.pl |
Poland | |
M. Sklodowska-Curie Memorial Cancer Centre | Recruiting |
Warsaw, Poland, 02-781 | |
Contact: Krzysztof Bujko, Prof. +48226439287 bujko@coi.waw.pl | |
Principal Investigator: Krzysztof Bujko, Prof. |
Principal Investigator: | Krzysztof Bujko, Prof. | Roentgena 5, 02-781 Warsaw, Poland |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Prof. Marek P. Nowacki, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology in Warsaw |
ClinicalTrials.gov Identifier: | NCT00833131 |
Other Study ID Numbers: |
PGBRJG0109 |
First Posted: | January 30, 2009 Key Record Dates |
Last Update Posted: | April 15, 2010 |
Last Verified: | April 2010 |
Rectal cancer Preoperative radiotherapy and consolidating chemotherapy |
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |